Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

356 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Natural history of osteonecrosis of the jaw in patients with multiple myeloma.
Badros A, Terpos E, Katodritou E, Goloubeva O, Kastritis E, Verrou E, Zervas K, Baer MR, Meiller T, Dimopoulos MA. Badros A, et al. Among authors: baer mr. J Clin Oncol. 2008 Dec 20;26(36):5904-9. doi: 10.1200/JCO.2008.16.9300. Epub 2008 Nov 17. J Clin Oncol. 2008. PMID: 19018084
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.
Badros A, Burger AM, Philip S, Niesvizky R, Kolla SS, Goloubeva O, Harris C, Zwiebel J, Wright JJ, Espinoza-Delgado I, Baer MR, Holleran JL, Egorin MJ, Grant S. Badros A, et al. Among authors: baer mr. Clin Cancer Res. 2009 Aug 15;15(16):5250-7. doi: 10.1158/1078-0432.CCR-08-2850. Epub 2009 Aug 11. Clin Cancer Res. 2009. PMID: 19671864 Free PMC article. Clinical Trial.
Therapy-related B-lymphoblastic leukemia after multiple myeloma.
Kallen ME, Koka R, Singh ZN, Ning Y, Kocoglu MH, Badros AZ, Niyongere S, Duong VH, Emadi A, Baer MR. Kallen ME, et al. Among authors: baer mr. Leuk Res Rep. 2022 Nov 1;18:100358. doi: 10.1016/j.lrr.2022.100358. eCollection 2022. Leuk Res Rep. 2022. PMID: 36353199 Free PMC article.
Clinical outcomes of patients with acute myeloid leukemia and cardiovascular disease.
Sanchez-Petitto G, Goloubeva OG, Masur J, Childress J, Iqbal T, An M, Muhammad S, Lawson J, Li G, Barr B, Emadi A, Law JY, Lee ST, Duong VH, Baer MR, Niyongere S. Sanchez-Petitto G, et al. Among authors: baer mr. Leuk Res. 2024 Mar;138:107456. doi: 10.1016/j.leukres.2024.107456. Epub 2024 Feb 20. Leuk Res. 2024. PMID: 38442593
Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420.
Lee EJ, George SL, Caligiuri M, Szatrowski TP, Powell BL, Lemke S, Dodge RK, Smith R, Baer M, Schiffer CA. Lee EJ, et al. J Clin Oncol. 1999 Sep;17(9):2831-9. doi: 10.1200/JCO.1999.17.9.2831. J Clin Oncol. 1999. PMID: 10561359 Clinical Trial.
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
Farag SS, George SL, Lee EJ, Baer M, Dodge RK, Becknell B, Fehniger TA, Silverman LR, Crawford J, Bloomfield CD, Larson RA, Schiffer CA, Caligiuri MA. Farag SS, et al. Clin Cancer Res. 2002 Sep;8(9):2812-9. Clin Cancer Res. 2002. PMID: 12231521 Clinical Trial.
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.
Baer MR, George SL, Caligiuri MA, Sanford BL, Bothun SM, Mrózek K, Kolitz JE, Powell BL, Moore JO, Stone RM, Anastasi J, Bloomfield CD, Larson RA. Baer MR, et al. J Clin Oncol. 2008 Oct 20;26(30):4934-9. doi: 10.1200/JCO.2008.17.0472. Epub 2008 Jun 30. J Clin Oncol. 2008. PMID: 18591543 Free PMC article. Clinical Trial.
356 results